NCT04670016 2026-04-15
HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers
University of Calgary
Completed
Clinical Trials
11 trialsNCT04185038 2026-04-13
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Seattle Children's Hospital
Phase 1 Recruiting
NCT05278208 2026-04-13
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Nationwide Children's Hospital
Phase 1/2 Recruiting
NCT06465199 2026-04-13
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Milton S. Hershey Medical Center
Phase 1/2 Recruiting
NCT05096481 2026-04-08
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Nationwide Children's Hospital
Phase 2 Recruiting
NCT07206849 2026-04-08
Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)
Nationwide Children's Hospital
Phase 2 Not yet recruiting
NCT05839379 2026-03-31
Targeted Pediatric High-Grade Glioma Therapy
Nationwide Children's Hospital
Recruiting
NCT07501156 2026-03-30
H3K27M-specific Immune Effector Cells Targeting DMG/DIPG
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Recruiting
NCT03605550 2026-03-27
A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma
Nationwide Children's Hospital
Phase 1 Active not recruiting
NCT06838676 2026-03-27
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
Nationwide Children's Hospital
Phase 2 Recruiting
NCT05843253 2026-03-20
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting